CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...

By now, you know that the COVID-19 vaccine is the best way to protect against severe COVID infections and reduce your chances of developing long COVID. You also know that the COVID-19 vaccine may have ...

New research from the U.S. Centers for Disease Control and Prevention suggests that people who receive Moderna’s COVID-19 vaccine might experience more side effects than those who get ...

Moderna said on Monday its combination vaccine to protect against both Covid and influenza generated a stronger immune response in adults aged 50 and over when compared to separate shots against the ...

The data, presented to the agency's Advisory Committee on Immunization Practices, is based on submissions to the agency's text messaging system v-safe and the Vaccine Adverse Event Reporting System, a ...

mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older ...

(Reuters) -Moderna Inc said on Wednesday early human trial data shows that a third dose of either its current COVID-19 shot or an experimental new vaccine candidate increases immunity against variants ...